DE3689715D1 - Verfahren und Reagenzien für die In-vitro-Synthese von Oligonukleotiden. - Google Patents

Verfahren und Reagenzien für die In-vitro-Synthese von Oligonukleotiden.

Info

Publication number
DE3689715D1
DE3689715D1 DE86307926T DE3689715T DE3689715D1 DE 3689715 D1 DE3689715 D1 DE 3689715D1 DE 86307926 T DE86307926 T DE 86307926T DE 3689715 T DE3689715 T DE 3689715T DE 3689715 D1 DE3689715 D1 DE 3689715D1
Authority
DE
Germany
Prior art keywords
oligonucleotides
reagents
methods
vitro synthesis
vitro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE86307926T
Other languages
English (en)
Other versions
DE3689715T2 (de
Inventor
Brian Carl Froehler
Mark Douglas Matteucci
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of DE3689715D1 publication Critical patent/DE3689715D1/de
Publication of DE3689715T2 publication Critical patent/DE3689715T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DE3689715T 1985-10-15 1986-10-14 Verfahren und Reagenzien für die In-vitro-Synthese von Oligonukleotiden. Expired - Fee Related DE3689715T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78728085A 1985-10-15 1985-10-15
US06/910,048 US4959463A (en) 1985-10-15 1986-09-19 Intermediates

Publications (2)

Publication Number Publication Date
DE3689715D1 true DE3689715D1 (de) 1994-04-21
DE3689715T2 DE3689715T2 (de) 1994-08-18

Family

ID=27120638

Family Applications (1)

Application Number Title Priority Date Filing Date
DE3689715T Expired - Fee Related DE3689715T2 (de) 1985-10-15 1986-10-14 Verfahren und Reagenzien für die In-vitro-Synthese von Oligonukleotiden.

Country Status (4)

Country Link
US (3) US4959463A (de)
EP (1) EP0219342B1 (de)
JP (3) JP2511005B2 (de)
DE (1) DE3689715T2 (de)

Families Citing this family (134)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5362866A (en) * 1983-09-02 1994-11-08 Molecular Biosystems, Inc. Oligonucleotide polymeric support system with an oxidation cleavable link
US4959463A (en) * 1985-10-15 1990-09-25 Genentech, Inc. Intermediates
FR2596761B1 (fr) * 1986-04-08 1988-05-20 Commissariat Energie Atomique Derives de nucleosides et leur utilisation pour la synthese d'oligonucleotides
US5204456A (en) * 1986-04-08 1993-04-20 Commissariat A L'energie Atomique Derivatives of nucleosides and their use for the synthesis of oligonucleotides
US4816571A (en) * 1987-06-04 1989-03-28 Applied Biosystems, Inc. Chemical capping by phosphitylation during oligonucleotide synthesis
US6756496B1 (en) 1988-09-23 2004-06-29 Isis Pharmaceuticals, Inc. Nucleoside hydrogen phosphonodithioate diesters and activated phosphonodithioate analogues
US5194599A (en) * 1988-09-23 1993-03-16 Gilead Sciences, Inc. Hydrogen phosphonodithioate compositions
US5262530A (en) 1988-12-21 1993-11-16 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
GB8902689D0 (en) * 1989-02-07 1989-03-30 Ici Plc Assay method
US5149798A (en) * 1989-04-06 1992-09-22 Worcester Foundation For Experimental Biology Process for synthesizing oligonucleotides and their analogs adaptable to large scale syntheses
US5256775A (en) * 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
US6300486B1 (en) * 1989-06-15 2001-10-09 Isis Pharmaceuticals, Inc. Large scale synthesis of oligonucleotides and their associated analogs
US5204455A (en) * 1989-06-15 1993-04-20 Froehler Brian C Monomethoxytrityl protected oligonucleotides bound to a solid support
US5164491A (en) * 1989-06-15 1992-11-17 Gilead Sciences Large scale synthesis of oligonucleotides and their associated analogs
EP0450060A1 (de) * 1989-10-26 1991-10-09 Sri International Dns-sequenzierung
US7037646B1 (en) 1990-01-11 2006-05-02 Isis Pharmaceuticals, Inc. Amine-derivatized nucleosides and oligonucleosides
US5321131A (en) * 1990-03-08 1994-06-14 Hybridon, Inc. Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling
US5166195A (en) * 1990-05-11 1992-11-24 Isis Pharmaceuticals, Inc. Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides
US5214134A (en) * 1990-09-12 1993-05-25 Sterling Winthrop Inc. Process of linking nucleosides with a siloxane bridge
US5432272A (en) * 1990-10-09 1995-07-11 Benner; Steven A. Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
US5594121A (en) * 1991-11-07 1997-01-14 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified purines
US5734020A (en) * 1991-11-20 1998-03-31 Cpg, Inc. Production and use of magnetic porous inorganic materials
US5610274A (en) * 1991-11-20 1997-03-11 Cpg, Inc. Production and use of magnetic porous inorganic materials
US6235887B1 (en) * 1991-11-26 2001-05-22 Isis Pharmaceuticals, Inc. Enhanced triple-helix and double-helix formation directed by oligonucleotides containing modified pyrimidines
TW393513B (en) * 1991-11-26 2000-06-11 Isis Pharmaceuticals Inc Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
ATE226093T1 (de) * 1991-11-26 2002-11-15 Isis Pharmaceuticals Inc Gesteigerte bildung von triple- und doppelhelices aus oligomeren mit modifizierten pyrimidinen
AU3250093A (en) 1991-12-12 1993-07-19 Gilead Sciences, Inc. Nuclease stable and binding competent oligomers and methods for their use
US5817781A (en) 1992-06-01 1998-10-06 Gilead Sciences, Inc. Modified internucleoside linkages (II)
US5583211A (en) * 1992-10-29 1996-12-10 Beckman Instruments, Inc. Surface activated organic polymers useful for location - specific attachment of nucleic acids, peptides, proteins and oligosaccharides
US6087491A (en) * 1993-01-08 2000-07-11 Hybridon, Inc. Extremely high purity oligonucleotides and methods of synthesizing them using dimer blocks
JPH08507752A (ja) * 1993-01-08 1996-08-20 ハイブライドン インコーポレイテッド 二量体ブロックの合成と二量体ブロックを使ったオリゴヌクレオチド結合法
US5476925A (en) * 1993-02-01 1995-12-19 Northwestern University Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups
EP0705335A1 (de) * 1993-06-23 1996-04-10 Genesys Pharma Inc. Antisense oligonukleotide und ihre verwendung bei der infektion mit menschlichem immunschwächevirus
US6653458B1 (en) 1993-09-03 2003-11-25 Isis Pharmaceuticals, Inc. Modified oligonucleotides
FR2714061B1 (fr) * 1993-12-16 1996-03-08 Genset Sa Procédé de préparation de polynucléotides sur support solide et appareil permettant sa mise en Óoeuvre.
US5637684A (en) * 1994-02-23 1997-06-10 Isis Pharmaceuticals, Inc. Phosphoramidate and phosphorothioamidate oligomeric compounds
US5623068A (en) * 1994-03-07 1997-04-22 Beckman Instruments, Inc. Synthesis of DNA using substituted phenylacetyl-protected nucleotides
US6639061B1 (en) 1999-07-07 2003-10-28 Isis Pharmaceuticals, Inc. C3′-methylene hydrogen phosphonate oligomers and related compounds
US5514789A (en) * 1994-04-21 1996-05-07 Barrskogen, Inc. Recovery of oligonucleotides by gas phase cleavage
US6214987B1 (en) 1994-09-02 2001-04-10 Andrew C. Hiatt Compositions for enzyme catalyzed template-independent formation of phosphodiester bonds using protected nucleotides
US5872244A (en) * 1994-09-02 1999-02-16 Andrew C. Hiatt 3' protected nucleotides for enzyme catalyzed template-independent creation of phosphodiester bonds
US5808045A (en) * 1994-09-02 1998-09-15 Andrew C. Hiatt Compositions for enzyme catalyzed template-independent creation of phosphodiester bonds using protected nucleotides
US6232465B1 (en) 1994-09-02 2001-05-15 Andrew C. Hiatt Compositions for enzyme catalyzed template-independent creation of phosphodiester bonds using protected nucleotides
US5763594A (en) * 1994-09-02 1998-06-09 Andrew C. Hiatt 3' protected nucleotides for enzyme catalyzed template-independent creation of phosphodiester bonds
US5990300A (en) * 1994-09-02 1999-11-23 Andrew C. Hiatt Enzyme catalyzed template-independent creation of phosphodiester bonds using protected nucleotides
US5639875A (en) * 1995-02-01 1997-06-17 Hybridon, Inc. Methods for H-phosphonate syntheis of oligonucleotides using triphosgene
US5683875A (en) * 1995-05-04 1997-11-04 Hewlett-Packard Company Method for detecting a target nucleic acid analyte in a sample
US5955599A (en) * 1995-06-01 1999-09-21 Hybridon, Inc. Process for making oligonucleotides containing o- and s- methylphosphotriester internucleoside linkages
US6531589B1 (en) 1995-06-01 2003-03-11 Hybridon, Inc. Base protecting groups and synthons for oligonucleotide synthesis
US5962674A (en) * 1995-06-01 1999-10-05 Hybridon, Inc. Synthesis of oligonucleotides containing alkylphosphonate internucleoside linkages
WO1996039414A1 (en) * 1995-06-01 1996-12-12 Hybridon, Inc. Novel base protecting groups for oligonucleotide synthesis
US6140482A (en) * 1995-06-01 2000-10-31 Hybridon, Inc. Primary phosphoramidate internucleoside linkages and oligonucleotides containing the same
US5856464A (en) * 1995-06-07 1999-01-05 Lajolla Pharmaceutical Company Selective capping solution phase oligonucleotide synthesis
WO1997014706A1 (en) 1995-10-19 1997-04-24 Nexstar Pharmaceuticals, Inc. Method for solution phase synthesis of oligonucleotides
US5705629A (en) * 1995-10-20 1998-01-06 Hybridon, Inc. Methods for H-phosphonate synthesis of mono- and oligonucleotides
WO1998017675A1 (en) * 1996-10-18 1998-04-30 Hybridon, Inc. Improved methods for h-phosphonate synthesis of mono- and oligonucleotides
US5902881A (en) * 1997-03-03 1999-05-11 Isis Pharmaceuticals, Inc. Reagent useful for synthesizing sulfurized oligonucleotide analogs
US5760209A (en) * 1997-03-03 1998-06-02 Isis Pharmaceuticals, Inc. Protecting group for synthesizing oligonucleotide analogs
ES2131463B1 (es) 1997-04-08 2000-03-01 Lilly Sa Derivados de ciclopropilglicina con propiedades farmaceuticas.
US6242591B1 (en) * 1997-10-15 2001-06-05 Isis Pharmaceuticals, Inc. Synthesis of sulfurized 2'-substituted oligonucleotides
US6114519A (en) * 1997-10-15 2000-09-05 Isis Pharmaceuticals, Inc. Synthesis of sulfurized oligonucleotides
US6441150B1 (en) * 1997-12-16 2002-08-27 Isis Pharmaceuticals, Inc. Compounds for the Synthesis of Nucleotide or oligonucleotide phosphoramidites
US7273933B1 (en) * 1998-02-26 2007-09-25 Isis Pharmaceuticals, Inc. Methods for synthesis of oligonucleotides
US6207819B1 (en) 1999-02-12 2001-03-27 Isis Pharmaceuticals, Inc. Compounds, processes and intermediates for synthesis of mixed backbone oligomeric compounds
CA2370478A1 (en) 1999-03-24 2000-09-28 Serge L. Beaucage N-acylphosphoramidites and their use in oligonucleotide synthesis
US6932943B1 (en) 2001-01-26 2005-08-23 Third Wave Technologies Nucleic acid synthesizers
US20030072689A1 (en) * 2001-08-15 2003-04-17 Third Wave Technologies, Inc. Polymer synthesizer
US7435390B2 (en) * 2001-01-26 2008-10-14 Third Wave Technologies, Inc. Nucleic acid synthesizers
US20080261220A1 (en) * 2000-11-30 2008-10-23 Third Wave Technologies, Inc. Nucleic Acid Detection Assays
AU2002220870A1 (en) * 2000-12-05 2002-06-18 Avecia Limited Process for the preparation of phosphorothionate oligonucleotides
WO2002081476A1 (en) * 2001-04-06 2002-10-17 Micrologix Biotech, Inc. Thiophosphate nucleic acid-based compounds
AU2002353001A1 (en) 2001-12-03 2003-06-17 The Government Of The United States Of America, Represented By The Secretary Of The Department Of He Thermolabile hydroxyl protecting groups and methods of use
US20060009409A1 (en) 2002-02-01 2006-01-12 Woolf Tod M Double-stranded oligonucleotides
EP3415625A1 (de) 2002-02-01 2018-12-19 Life Technologies Corporation Doppelsträngige oligonukleotide
US20030166282A1 (en) 2002-02-01 2003-09-04 David Brown High potency siRNAS for reducing the expression of target genes
US20050009051A1 (en) * 2002-09-27 2005-01-13 Board Of Regents, The University Of Texas Diagnosis of mould infection
EP1638587A4 (de) 2003-02-14 2007-04-18 Univ Missouri Empfängnisverhütende verfahren und zusammensetzungen betreffend proteasomale störung
JP2007526772A (ja) * 2004-02-27 2007-09-20 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ インサイチュー配列決定用ポロニー蛍光ビーズ
EP2290071B1 (de) 2004-05-28 2014-12-31 Asuragen, Inc. Verfahren und Zusammensetzungen mit MicroRNA
DE602005021525D1 (de) 2004-09-14 2010-07-08 Univ Colorado R behandlung mit bucindolol
WO2006137941A2 (en) 2004-11-12 2006-12-28 Ambion, Inc. Methods and compositions involving mirna and mirna inhibitor molecules
WO2006065751A2 (en) 2004-12-13 2006-06-22 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Cpg oligonucleotide prodrugs, compositions thereof and associated therapeutic methods
EP1871913A2 (de) * 2005-03-25 2008-01-02 Ambion, Inc. Verfahren und zusammensetzungen zur verringerung abundanter rna-transkripte
US20090131348A1 (en) 2006-09-19 2009-05-21 Emmanuel Labourier Micrornas differentially expressed in pancreatic diseases and uses thereof
AU2007333109A1 (en) 2006-12-08 2008-06-19 Asuragen, Inc. Functions and targets of let-7 micro RNAs
US9605035B2 (en) 2008-01-10 2017-03-28 Research Development Foundation Vaccines and diagnostics for the ehrlichioses
PL2245464T3 (pl) 2008-01-25 2017-08-31 Multivir Inc. Biomarkery p53
EP2990487A1 (de) 2008-05-08 2016-03-02 Asuragen, INC. Zusammensetzungen und verfahren in zusammenhang mit der mirna-modulation von neovaskularisation oder angiogenese
US20100047876A1 (en) * 2008-08-08 2010-02-25 President And Fellows Of Harvard College Hierarchical assembly of polynucleotides
US20100135904A1 (en) 2008-11-07 2010-06-03 Research Development Foundation Compositions and methods for the inhibition of cripto / grp78 complex formation and signaling
US9084781B2 (en) 2008-12-10 2015-07-21 Novartis Ag MEK mutations conferring resistance to MEK inhibitors
EP2379720B1 (de) 2009-01-20 2016-08-17 Alona Zilberberg Durch den promoter mir-21 angetriebene gezielte krebstherapie
US20110045080A1 (en) * 2009-03-24 2011-02-24 William Marsh Rice University Single-Walled Carbon Nanotube/Bioactive Substance Complexes and Methods Related Thereto
JP5785942B2 (ja) 2009-06-29 2015-09-30 ルミネックス コーポレーション ヘアピンコンフォメーションを有するキメラプライマーおよびその使用法
EP2470560B1 (de) 2009-08-28 2015-06-10 Research Development Foundation Urocortin-2-analoga und ihre verwendung
US9512481B2 (en) 2009-09-11 2016-12-06 The Regents Of The University Of Colorado, A Body Corporate Polymorphisms in the PDE3A gene
EP2515899B1 (de) 2009-12-23 2016-05-25 ARCA biopharma, Inc. Verfahren und zusammensetzungen für herz-kreislauf-erkrankungen und -leiden
EP2535411A4 (de) 2010-02-12 2013-07-03 M & D Inc Sonde für die diagnose von hpv-genotypen und analyseverfahren dafür
WO2011106298A1 (en) 2010-02-25 2011-09-01 Dana-Farber Cancer Institute, Inc. Braf mutations conferring resistance to braf inhibitors
ES2631458T3 (es) 2010-03-04 2017-08-31 Interna Technologies B.V. Molécula de ARNmi definida por su fuente y sus usos terapéuticos en el cáncer asociado a la EMT
US20130131148A1 (en) 2010-04-12 2013-05-23 Noam Shomron Micro-rna for cancer diagnosis, prognosis and therapy
JP5908466B2 (ja) 2010-06-09 2016-04-26 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｒａｆ及びｍｅｋ阻害剤に対する耐性を与えるｍｅｋ１変異
NZ719520A (en) 2010-07-06 2017-07-28 Int Tech Bv Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway
WO2012048341A1 (en) 2010-10-08 2012-04-12 President And Fellows Of Harvard College High-throughput single cell barcoding
EP2640851A2 (de) 2010-11-17 2013-09-25 Asuragen, Inc. Mirna als biomarker zur unterscheidung zwischen benignen und malignen neoplasien der schilddrüse
EP2474617A1 (de) 2011-01-11 2012-07-11 InteRNA Technologies BV MIR zur Behandlung von Neoangiogenese
SG192252A1 (en) 2011-02-03 2013-09-30 Mirna Therapeutics Inc Synthetic mimics of mir-34
CN103459598B (zh) 2011-02-03 2016-08-10 米尔纳医疗股份有限公司 Mir-124的合成模拟物
WO2013040251A2 (en) 2011-09-13 2013-03-21 Asurgen, Inc. Methods and compositions involving mir-135b for distinguishing pancreatic cancer from benign pancreatic disease
CA2844577A1 (en) 2011-09-13 2013-03-21 Ottawa Hospital Research Institute Microrna inhibitors
EP2766498B1 (de) 2011-10-14 2019-06-19 President and Fellows of Harvard College Sequenzierung durch strukturanordnung
WO2013063519A1 (en) 2011-10-26 2013-05-02 Asuragen, Inc. Methods and compositions involving mirna expression levels for distinguishing pancreatic cysts
EP3369818B1 (de) 2011-12-22 2021-06-09 InteRNA Technologies B.V. Mirna zur behandlung von kopf-hals-karzinom
US9914967B2 (en) 2012-06-05 2018-03-13 President And Fellows Of Harvard College Spatial sequencing of nucleic acids using DNA origami probes
CN104662544B (zh) 2012-07-19 2018-08-03 哈佛大学校长及研究员协会 利用核酸存储信息的方法
US9993522B2 (en) 2012-09-18 2018-06-12 Uti Limited Partnership Treatment of pain by inhibition of USP5 de-ubiquitinase
US20140100124A1 (en) 2012-10-04 2014-04-10 Asuragen, Inc. Diagnostic mirnas for differential diagnosis of incidental pancreatic cystic lesions
US9476089B2 (en) 2012-10-18 2016-10-25 President And Fellows Of Harvard College Methods of making oligonucleotide probes
EP2917348A1 (de) 2012-11-06 2015-09-16 InteRNA Technologies B.V. Kombination zur behandlung von erkrankungen oder zuständen im zusammenhang mit melanom oder behandlung von erkrankungen und zuständen im zusammenhang mit aktivierten b-raf-signalweg
US10125373B2 (en) 2013-01-22 2018-11-13 Arizona Board Of Regents On Behalf Of Arizona State University Geminiviral vector for expression of rituximab
WO2014134179A1 (en) 2013-02-28 2014-09-04 The Board Of Regents Of The University Of Texas System Methods for classifying a cancer as susceptible to tmepai-directed therapies and treating such cancers
EP3578666A1 (de) 2013-03-12 2019-12-11 President and Fellows of Harvard College Verfahren zur erzeugung einer dreidimensionalen nukleinsäure mit matrix
EP3404116B1 (de) 2013-03-15 2022-10-19 The University of Chicago Verfahren und zusammensetzungen in zusammenhang mit t-zell aktivität
EP3065706A4 (de) 2013-11-08 2017-11-29 Baylor Research Institute Nukleare lokalisierung von glp-1 zur stimulation der herzmuskelregenerierung und reversion von herzversagen
EP3259346A4 (de) 2015-02-20 2018-07-11 Baylor College of Medicine P63-inaktivierung zur behandlung von herzinsuffizienz
CA3019635A1 (en) 2016-03-31 2017-10-05 Baylor Research Institute Angiopoietin-like protein 8 (angptl8)
US10927379B2 (en) 2016-09-16 2021-02-23 Bio-Path Holdings, Inc. Combination therapy with liposomal antisense oligonucleotides
CA3079524A1 (en) 2017-11-03 2019-05-09 Interna Technologies B.V. Mirna molecule, equivalent, antagomir, or source thereof for treating and/or diagnosing a condition and/or a disease associated with neuronal deficiency or for neuronal (re)generation
MX2020012717A (es) 2018-05-25 2021-07-15 Arca Biopharma Inc Métodos y composiciones con bucindolol para el tratamiento de la fibrilación auricular.
IL302594A (en) 2020-11-09 2023-07-01 1E Therapeutics Ltd Methods based on catalytic sequences for the treatment or prevention of bacterial infections
KR20230126725A (ko) 2020-12-28 2023-08-30 1이 테라퓨틱스 엘티디. 침묵화를 위한 P21 mRNA 표적 부위
AU2021416356A1 (en) 2020-12-28 2023-08-10 1E Therapeutics, Ltd. P21 mrna targeting dnazymes
WO2022217283A1 (en) 2021-04-08 2022-10-13 Joslin Diabetes Center, Inc. Methods of diagnosing and predicting renal decline
WO2024015766A1 (en) 2022-07-12 2024-01-18 Topogene Inc. Scalable, submicron-resolution replication of dna arrays

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687808A (en) * 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US4190495A (en) 1976-09-27 1980-02-26 Research Corporation Modified microorganisms and method of preparing and using same
FR2476092A1 (fr) * 1980-02-20 1981-08-21 Commissariat Energie Atomique Procede de synthese de polynucleotides
US4458066A (en) * 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4469863A (en) * 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
JP2547714B2 (ja) * 1981-10-23 1996-10-23 モルキユラ− バイオシステムズ インコ−ポレテツド オリゴヌクレオチド治療剤及びその製法
IL69196A0 (en) * 1982-08-20 1983-11-30 Genex Corp Solid phase synthesis of oligonucleotides
DE3239888A1 (de) * 1982-10-28 1984-05-03 Hubert Prof. Dr. 2000 Hamburg Köster Verfahren zur herstellung von oligonucleosidphosphonaten
US4547569A (en) * 1982-11-24 1985-10-15 The United States Of America As Represented By The Department Of Health And Human Services Intercalating agents specifying nucleotides
FR2540122B1 (fr) * 1983-01-27 1985-11-29 Centre Nat Rech Scient Nouveaux composes comportant une sequence d'oligonucleotide liee a un agent d'intercalation, leur procede de synthese et leur application
DE3329892A1 (de) * 1983-08-18 1985-03-07 Köster, Hubert, Prof. Dr., 2000 Hamburg Verfahren zur herstellung von oligonucleotiden
DE3332068A1 (de) * 1983-09-06 1985-03-21 Hoechst Ag, 6230 Frankfurt Verfahren zur herstellung von nukleosidalkyl-, aralkyl- und arylphosphoniten und -phosphonaten
US4507433A (en) * 1983-10-07 1985-03-26 The Johns Hopkins University Preparation of oligodeoxyribonucleoside alkyl or arylphosphonates
SE466208B (sv) * 1983-12-20 1992-01-13 California Inst Of Techn Enkelstraengad aminoderivat av oligonukleotider och foerfarande foer framstaellning daerav
US4959463A (en) * 1985-10-15 1990-09-25 Genentech, Inc. Intermediates

Also Published As

Publication number Publication date
JP2705914B2 (ja) 1998-01-28
JP2705913B2 (ja) 1998-01-28
DE3689715T2 (de) 1994-08-18
EP0219342A3 (en) 1987-12-16
US4959463A (en) 1990-09-25
EP0219342A2 (de) 1987-04-22
EP0219342B1 (de) 1994-03-16
JP2511005B2 (ja) 1996-06-26
JPS62116593A (ja) 1987-05-28
JPH0812697A (ja) 1996-01-16
JPH0812698A (ja) 1996-01-16
US5264566A (en) 1993-11-23
US5548076A (en) 1996-08-20

Similar Documents

Publication Publication Date Title
DE3689715D1 (de) Verfahren und Reagenzien für die In-vitro-Synthese von Oligonukleotiden.
DE69009545D1 (de) Verfahren zur Sprachanalyse und -synthese.
DE3673548D1 (de) Hydrokonversionskatalysator und verfahren.
DE3780560D1 (de) Fuehler und verfahren zu dessen herstellung.
DE3672353D1 (de) Hochfestes feldspataehnliches porzellan und verfahren zu seiner herstellung.
DE3681992D1 (de) Ruehrwerk zur benutzung in biochemischen reaktionen.
DE3677044D1 (de) Verfahren zur herstellung von emulsionen und die so erhaltenen emulsionen.
DE68924498D1 (de) Verfahren für die Herstellung von Perfluoroxyethylen- und Perfluoroxypropyleneinheiten enthaltenden Perfluoropolyäthern.
DE3650264D1 (de) Aluminiumnitridsinterkörper und Verfahren zu seiner Herstellung.
DE3751691D1 (de) Rotierende Angioplastiesysteme für die klinische Anwendung
DE3777141D1 (de) Mikrokapseln und verfahren zur herstelllung.
DE3765348D1 (de) Produkte und verfahren fuer die flockung von waesserigen suspensionen.
DE3685782D1 (de) Magnesiumhydroxyd und verfahren zu seiner herstellung.
DE68908712D1 (de) Edelmetall enthaltende katalysatoren und verfahren zur herstellung.
DE69132830D1 (de) Verfahren und Reagentien für die Identifikation von Bakterien
DE3578454D1 (de) Klinisches analysesystem und verfahren.
NZ215453A (en) Method of synthesis of oligonucleotides and assays
DE69031657D1 (de) Verfahren und erzeugnisse für die asbestbehandlung
DE3873836D1 (de) Aluminiumborat-whisker und verfahren zu ihrer herstellung.
DE68922716D1 (de) Elektrophoreseplatte und Verfahren zu ihrer Herstellung.
DE3788205D1 (de) Etikett und Verfahren zu seiner Herstellung.
BR8800586A (pt) Catalisador e processo de preparacao do mesmo
DE69021465D1 (de) Verfahren und Form für kaschierte Paneele.
DE68909283D1 (de) Verfahren und System für die automatische Synthese chemischer Produkte.
FI884884A (fi) Katalyyttinen vahanpoistomenetelmä

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee